Table S11 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Table S11 shows the summary of glecirasib's in vivo safety pharmacology studies.
Fields of Study & Subjects
Protein Kinase Regulation and GTPase Signaling
Melanoma and MAPK Pathways
Protein Tyrosine Phosphatases
Publication details
- Publication date
- 16 March 2026
- Language
- EN